Literature DB >> 1515552

Biological effects of recombinant vaccinia virus-expressed interleukin 4.

M E Andrew1, B E Coupar.   

Abstract

Recombinant vaccinia viruses expressing murine interleukin 4 (IL-4), either alone or together with interleukin 2 (IL-2) or gamma interferon (gamma-IFN), were constructed. Unlike IL-2, IL-4 expressing viruses were not cleared from immunodeficient mice and the mice died. As they died more rapidly than immunodeficient mice inoculated with a control virus, it appeared that IL-4 contributed to their death and the IL-4 mediated toxicity was confirmed in normal immunocompetent mice. The toxicity was reversed by co-expression of either IL-2 or gamma-IFN, probably due to virus clearance and therefore lower levels of circulating IL-4. Vaccinia virus-expressed IL-4 did not increase antibody or natural killer cell levels and caused a slight decrease in cytotoxic T lymphocyte levels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1515552     DOI: 10.1016/1043-4666(92)90068-3

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  10 in total

1.  Creation of killer poxvirus could have been predicted.

Authors:  A Müllbacher; M Lobigs
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.

Authors:  Douglas W Grosenbach; Robert Jordan; Dennis E Hruby
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

Review 3.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

Authors:  R J Jackson; A J Ramsay; C D Christensen; S Beaton; D F Hall; I A Ramshaw
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus.

Authors:  Teresa R Johnson; Seokmann Hong; Luc Van Kaer; Yasuhiko Koezuka; Barney S Graham
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination.

Authors:  Douglas W Grosenbach; Robert Jordan; David S King; Aklile Berhanu; Travis K Warren; Dana L Kirkwood-Watts; Shanthakumar Tyavanagimatt; Ying Tan; Rebecca L Wilson; Kevin F Jones; Dennis E Hruby
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 4.169

7.  Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo.

Authors:  D P Sharma; A J Ramsay; D J Maguire; M S Rolph; I A Ramshaw
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

8.  Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.

Authors:  Nanhai Chen; Clifford J Bellone; Jill Schriewer; Gelita Owens; Torgny Fredrickson; Scott Parker; R Mark L Buller
Journal:  Virology       Date:  2010-11-10       Impact factor: 3.513

9.  Application of Parallel Reaction Monitoring to the Development and Validation of a Quantitative Assay for ST-246 in Human Plasma.

Authors:  Alexander A Chernonosov; Galina A Oleinik; Vladimir V Koval
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

10.  Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon.

Authors:  G P Bembridge; J A Lopez; R Cook; J A Melero; G Taylor
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.